# Phyllodes Tumour Management > Phyllodes tumour for NEET-PG Surgery: fibroepithelial tumour of the forties, benign-borderline-malignant grading, 1 cm margins and no axillary dissection. - Canonical URL: https://prepelephant.com/topics/neet-pg/surgery/phyllodes-tumour - Exam / course: NEET-PG · Subject: Surgery - Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team - First published: 2026-10-02 - Last updated: 2026-10-02 - How to cite: "Phyllodes Tumour Management", PrepElephant, https://prepelephant.com/topics/neet-pg/surgery/phyllodes-tumour ## Direct answer Like a fibroadenoma, only a decade older and in a hurry: the phyllodes tumour is a fibroepithelial neoplasm of women typically in their forties, presenting as a rapidly enlarging breast lump — often a long-standing "fibroadenoma" that suddenly grows — with leaf-like epithelial clefts and a cellular stroma that decides behaviour. Grading into benign, borderline and malignant rests on stromal cellularity, atypia, mitotic activity and stromal overgrowth. Treatment is wide local excision with a margin of at least 1 cm; axillary dissection is not performed even for malignant phyllodes, because it spreads haematogenously — to lung and bone — not through lymphatics. ## What you must remember - Age signature: fibroadenoma in the twenties, phyllodes in the forties (a viva shorthand examiners reward); a "fibroadenoma" enlarging quickly in a middle-aged woman is a phyllodes until proven otherwise. - Macroscopy: circumscribed, lobulated, grey-white with whorled clefts; microscopy: leaf-like papillae lined by benign epithelium over a hypercellular stroma — the stroma is the tumour. - Grading: benign (mild cellularity, few mitoses), borderline (moderate atypia and mitotic activity) and malignant (marked stromal overgrowth, severe atypia, frequent mitoses) — metastatic potential rises with grade. - The margin is the operation: at least 1 cm of healthy tissue, because the tumour's pseudocapsule invites local recurrence when enucleated; recurrence even of benign histology is well recognised. - No axillary dissection: nodal metastasis is rare (a small percentage) — verify clinically, but the spread is haematogenous, with lung the commonest distant site, then bone. - Mastectomy is reserved for tumours too large for breast-conserving clearance, for recurrent disease, or where margins cannot be achieved relative to breast size. - Core biopsy (not FNAC) before surgery: cytology cannot reliably separate cellular fibroadenoma from phyllodes; imaging may show a rapidly growing lobulated solid mass. - Local recurrence is managed by re-excision with wider margins; distant metastases from malignant phyllodes behave like soft-tissue sarcoma and are treated systemically. - Giant phyllodes may ulcerate the skin with dilated overlying veins — and are still, in a proportion, histologically benign. ## Deciding the operation for a fast-growing lump A 46-year-old reports that a lump known for six years has doubled in size over five months; examination finds an 8 cm, smooth, mobile mass with a prominent vein but no nodes. Core biopsy reports a spindle-cell fibroepithelial tumour favouring benign phyllodes, with the caveat that grading requires the whole lesion — the clinical hinge, since definitive classification comes from the excised specimen. Because the tumour is 8 cm in a moderate breast, achieving a 1 cm margin by wide local excision is feasible but will distort the breast; oncoplastic planning (therapeutic mammoplasty or local tissue rearrangement) lets the surgeon take generous margins without mutilation. The definitive histology reports benign phyllodes, completely excised — she is surveyed clinically and by imaging, with counselling that recurrence, usually local, occurs in a minority even after adequate excision. Vary the histology to malignant with stromal overgrowth and a 15 cm size: the discussion moves to mastectomy (breast conservation rarely achieves margins), still with clinical axillary assessment rather than dissection, and a staging chest CT — because the threat in malignant phyllodes is haematogenous, to the lungs, exactly like a sarcoma. ## Where students slip The commonest error is enucleation — shelling the tumour out "like a fibroadenoma" through its pseudocapsule; local recurrence of phyllodes after enucleation is the standard cautionary tale, and the examined answer is a 1 cm margin. The second is the reflex to operate on the axilla: malignant-sounding breast tumour plus no nodes still does not justify clearance, and the candidate who explains the haematogenous, sarcoma-like biology of malignant phyllodes — lung secondaries, node-negative — demonstrates the concept rather than the reflex. The third is diagnostic: trusting FNAC to distinguish cellular fibroadenoma from phyllodes; cores, and often the whole specimen, make that call. ## Frequently asked questions ### In which age group does phyllodes tumour typically occur? Most often in the forties — about two decades after the peak of fibroadenoma — and rapid growth of a long-standing lump in this age group is the classic history. ### On what features is phyllodes tumour graded? Stromal cellularity, nuclear atypia, mitotic activity and stromal overgrowth define benign, borderline and malignant categories, which predict local recurrence and metastatic behaviour. ### What margin is required at excision? At least 1 cm of healthy tissue around the tumour; enucleation along the pseudocapsule invites local recurrence even in histologically benign lesions. ### Is axillary dissection indicated in malignant phyllodes? No — spread is haematogenous rather than lymphatic, nodal metastasis is rare, and the axilla is assessed clinically; dissection is reserved for the exceptional proven nodal disease. ### Where does malignant phyllodes metastasise? Haematogenously, behaving like a soft-tissue sarcoma — lung is the commonest site, followed by bone — with metastases managed systemically. ### When is mastectomy chosen? For tumours too large relative to the breast to achieve 1 cm clear margins with conservation, for local recurrence where further breast preservation is impossible, or at patient preference after counselling.